Search
forLearn
5 / 801 resultslearn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
learn RH410
learn TDM-105795
learn EUK 134
Research
5 / 867 resultsresearch Санитарно-химическое исследование анионитов, используемых в пищевой промышленности
Minoxidil combined with ATRA boosts hair growth better than minoxidil alone.
research DERMATOLOGICAL ASPECTS OF SIGNIFICANCE OF HYPERANDROGENIZM FOR POLYCYSTIC OVARY SYNDROME
Hirsutism and acanthosis nigricans are important for diagnosing PCOS; dermatologists play a key role in early detection and treatment.
research Minoxidil: effectiveness and prospects for use in the treatment of androgenetic alopecia
Minoxidil is an effective and safe treatment for common hair loss when applied to the skin, but more research is needed for optimal use.
research Interventions for nail psoriasis
Some systemic treatments work for nail psoriasis but can have serious side effects.
research Mechanical stretch induces hair regeneration through the alternative activation of macrophages
Mechanical stretching of the skin can promote hair growth by activating certain immune cells.
Community Join
5 / 1000+ resultscommunity HMI 115 hasn't done phase one yet for AGA?
User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.
community (Serious) Updates and discussion, new treatments in development
Finasteride, minoxidil, and derma rolling are currently the best treatments for hair loss. New treatments like TDM-105795, GT20029, PP405, HMI 115, Tsuji, Scube 3, RU, JW0061, Topilutamide, and verteporfin show promise but have uncertain timelines.
community HMI 115 Phase 2 - Leaked pics from Discord
The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community Hope Medicine announces HMI-115 phase II clinical trial for androgenetic alopecia in China
Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.